Clinical observation of GEMOX and FOLFOX regimens as first-line chemotherapy for advanced duodenal cancer
PAN Jun
QIN Shukui
YANG Ningrong
HUANG Wei
WANG Lin
Abstract：Objective To evaluate the efficacy and safety of GEMOX and FOLFOX regimens as first-line chemotherapy for advanced duodenal cancer.Methods From June 2008 to Jan 2016, 30 advanced duodenal cancer patients were analyzed.Only 20 patients received chemotherapy, including 9 patients of GEMOX regimen and 11 patients of FOLFOX regimen as first-line chemotherapy.The efficacy and safety were evaluated by RECIST 1.1 and NCI-CTC 4.0 criteria.Overall survival (OS) and progression-free survival (PFS) were analyzed by Kaplan-Meier method.Results Among patients receiving chemotherapy, CR and PR were not observed.For GEMOX regiem, 6 cases of SD and 3 cases of PD were observed with disease control rate (DCR) of 66.7%.For FOLFOX regiem, 4 cases of SD and 7 cases of PD were observed with DCR of 36.4%.No difference in DCR was observed between different regimes (P>0.05).The median OS of GEMOX and FOLFOX regimes were 27.9 months and 15.2 months(P=0.179).The median PFS of GEMOX regime was 8 months, superior to 4.4 months of FOLFOX regime (P=0.038).The major treatment-related side effects included leucopenia, neutropenia, nausea, vomiting, fatigue, erythra and etc, mainly in grade1-2.The median OS of patients receiving chemotherapy was 26.9 months, superior to 4.4 months of patients receiving non-chemotherapy (P<0.001).Conclusion Chemotherapy was effective in advanced duodenal cancer.Both GEMOX and FOLFOX regimes were effective and well-tolerated in the first-line chemotherapy.GEMOX had a longer PFS in first-line chemotherapy.
Keywords：Advanced duodenal cancerGEMOX regiemFOLFOX regiemFirst-line chemotherapy
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 535-539 )